scholarly journals Left Atrial Appendage Closure for Stroke Prevention in Patients with Atrial Fibrillation and Hereditary Hemorrhagic Telangiectasia

2012 ◽  
Vol 2012 ◽  
pp. 1-3
Author(s):  
Sebastiaan Velthuis ◽  
Martin J. Swaans ◽  
Johannes J. Mager ◽  
Benno J. W. M. Rensing ◽  
Lucas V. A. Boersma ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Oral Anticoagulation ◽  
Hereditary Hemorrhagic Telangiectasia ◽  
Left Atrial ◽  
Autosomal Dominant ◽  
Left Atrial Appendage ◽  
Good Alternative ◽  
Atrial Appendage ◽  
Bleeding Tendency ◽  
Vascular Abnormalities

Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting millions of individuals worldwide, and a major risk factor for disabling cerebral embolic stroke. Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant inherited disorder, characterized by vascular abnormalities with high-bleeding tendency and therefore intolerance for oral anticoagulation. We report a case of percutaneous closure of the left atrial appendage, which might be a good alternative strategy instead of chronic oral anticoagulation to protect patients with high-risk AF and HHT from cerebral embolic strokes.

scholarly journals Left atrial appendage closure in atrial fibrillation patients with prior major bleeding or ineligible for oral anticoagulation

2019 ◽  
Vol 27 (12) ◽  
pp. 613-620 ◽  
Author(s):  
L. I. S. Wintgens ◽  
V. M. M. Vorselaars ◽  
M. N Klaver ◽  
M. J. Swaans ◽  
A. Alipour ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Major Bleeding ◽  
Oral Anticoagulation ◽  
Left Atrial ◽  
Left Atrial Appendage ◽  
Atrial Appendage ◽  
Left Atrial Appendage Closure

scholarly journals Left Atrial Appendage Exclusion for Stroke Prevention in Atrial Fibrillation

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Taral K. Patel ◽  
Clyde W. Yancy ◽  
Bradley P. Knight
Keyword(s):  
Atrial Fibrillation ◽  
Oral Anticoagulation ◽  
Stroke Prevention ◽  
Left Atrial ◽  
Left Atrial Appendage ◽  
Critical Role ◽  
Standard Of Care ◽  
Atrial Appendage ◽  
Current Standard ◽  
Public Health Burden

The public health burden of atrial fibrillation (AF) and associated thromboembolic stroke continues to grow at alarming rates. AF leads to a fivefold increase in the risk of stroke. Therefore, stroke prevention remains the most critical aspect of AF management. Current standard of care focuses on oral systemic anticoagulation, most commonly with warfarin and now with newer agents such as dabigatran, rivaroxaban, and apixaban. However, the challenges and limitations of oral anticoagulation have been well documented. Given the critical role of the left atrial appendage (LAA) in the genesis of AF-related thromboembolism, recent efforts have targeted removal or occlusion of the LAA as an alternative strategy for stroke prevention, particularly in patients deemed unsuitable for oral anticoagulation. This paper highlights recent advances in mechanical exclusion of the LAA. The problem of AF and stroke is briefly summarized, followed by an explanation for the rationale behind LAA exclusion for stroke prevention. After briefly reviewing the history of LAA exclusion, we highlight the most promising LAA exclusion devices currently available. Finally, we discuss future challenges and opportunities in this growing field.

scholarly journals Left atrial appendage occlusion with Amplatzer Cardio Plug is an acceptable therapeutic option for prevention of stroke recurrence in patients with non-valvular atrial fibrillation and contraindication or failure of oral anticoagulation with acenocumarol

2016 ◽  
Vol 74 (3) ◽  
pp. 219-222
Author(s):  
Maximiliano A. Hawkes ◽  
Lucía Pertierra ◽  
Federico Rodriguez-Lucci ◽  
Virginia A. Pujol-Lereis ◽  
Sebastián F. Ameriso
Keyword(s):  
Atrial Fibrillation ◽  
Oral Anticoagulation ◽  
Left Atrial ◽  
Left Atrial Appendage ◽  
Therapeutic Option ◽  
Atrial Appendage ◽  
Stroke Recurrence ◽  
Left Atrial Appendage Occlusion ◽  
Hemorrhagic Risk ◽  
Procedural Complications

ABSTRACT Left atrial appendage occlusion (LAAO) appears as a therapeutic option for some atrial fibrillation patients not suitable for oral anticoagulation because an increased hemorrhagic risk or recurrent ischemic events despite anticoagulant treatment. Methods Report of consecutive atrial fibrillation patients treated with LAAO with Amplatzer Cardio Plug because contraindication or failure of oral anticoagulation with acenocumarol. CHA2DS2VASC, HAS-BLED, NIHSS, mRS, procedural complications and outcome were assessed. Seven patients (73 ± 6 year-old) were treated after intracerebral (n = 5) and gastrointestinal (n = 1) hemorrhages or ischemic stroke recurrence while on acenocumarol (n = 1). Results Mean follow up was 18 months. Baseline CHA2DS2Vasc y HAS-BLED scores were 5.6 ± 0.7 and 4.1 ± 0.3 respectively. There were no strokes or deaths. There was only one non-serious adverse event. Conclusion LAAO with ACP appears as a feasible therapeutic option for stroke prevention in patients with atrial fibrillation and failure or contraindication to acenocumarol.

Sign in / Sign up

Export Citation Format

Share Document